Receptor-Mediated Gene Delivery Using Chitosan Derivatives In Vitro and In Vivo

Article Preview

Abstract:

The key strategy for the advancement of gene therapy is the development of an efficient targeted gene delivery system into cells. The targeted gene delivery system is especially important in non-viral gene transfer which shows the relatively low transfection efficiency. It also opens the possibility of selective delivery of therapeutic plasmids to specific tissues. Chitosan has been considered to be a good candidate for gene delivery system, since it is already known as a biocompatible, biodegradable, and low toxic material with high cationic potential. However, low specificity and low transfection efficiency of chitosan need to be overcome prior to clinical trial. In this study, we focused on the chemical modification of chitosan for enhancement of cell specificity and transfection efficiency. Also, the potential of clinical application was investigated.

You might also be interested in these eBooks

Info:

Periodical:

Key Engineering Materials (Volumes 342-343)

Pages:

449-452

Citation:

Online since:

July 2007

Export:

Price:

Permissions CCC:

Permissions PLS:

Сopyright:

© 2007 Trans Tech Publications Ltd. All Rights Reserved

Share:

Citation:

[1] R. Christiano, Anticancer Res. Vol. 18 (1998), p.3241.

Google Scholar

[2] K. W. Leong, H. -Q. Mao, V.L. Truong-Le, K. Roy, S.M. Walsh, and J. T. August, J. Control Rel. Vol. 51 (1998) p.183.

Google Scholar

[3] K.Y. Lee, I.C. Kwon, Y.H. Kim, W.H. Jo, and S.Y. Jeong, J. Control Rel. Vol. 51 (1998), p.213.

Google Scholar

[4] G. Y. Wu, and C. H. Wu. Adv Drug Deliv Rev. Vol. 29 (1998), p.243.

Google Scholar

[5] G. Ashwell, and J. Harford. Ann Rev Biochem Vol. 51 (1982), p.531.

Google Scholar

[6] T. H. Kim, I. K. Park, J.W. Nah, Y.J. Choi, and C.S. Cho, Biomaterials. Vol. 25 (2004), p.3783.

Google Scholar

[7] T. H. Kim, S. I. Kim, T. Akaike, and C. S. Cho, J. Control Rel. Vol. 105 (2005), p.354.

Google Scholar

[8] S. Raychaudhuri, and K. L. Rock, Nat. Biotechnol. Vol. 16 (1998) p.1025.

Google Scholar

[9] C. Foged, A. Sundblad, and L. Hovgaard, Pharm. Res. Vol. (2002) p.19.

Google Scholar

[10] J. Banchereau, and R. M. Steinman, Nature Vol. 392 (1998) p.245.

Google Scholar

[11] R. M. Steinman, Pathol. Biol. Vol. 51 (2003) p.59.

Google Scholar

[12] F. Liu, and L. Huang, J. Control Rel. Vol. 78 (2002) p.259.

Google Scholar

[13] S. S. Diebold, M. Cotton, E. Wagner, and M. Zenke, Adv. Exp. Med. Biol. Vol. 451 (1998) p.449.

Google Scholar

[14] W. Jiang, W. J. Swiggard, C. Heufler, M. Peng, A. Mirza, R. M. Steinman, and M. C. Nussenzweig, Nature Vol. 375 (1995) p.151.

DOI: 10.1038/375151a0

Google Scholar

[15] T. H. Kim, J. W. Nah, M. H. Cho, T. G. Park, and C. S. Cho, J. Nanosci. Nanotechnol. (2006) in press.

Google Scholar

[16] T. H. Kim, H. Jin, H. W. Kim, M. H. Cho, and C. S. Cho, Mol. Cancer Ther. (2006) Vol. 5 p.1723.

Google Scholar

[17] N. Haicheur, B. Escudier, T. Dorval, et al. Clin. Exp. Immunol. Vol. 119 (2000).

Google Scholar

[16] Fig. 5. Western blot analysis of mIL-12 p.70 and mIFN-� in tumor tissues of BALB/c mice bearing CT-26 carcinoma cells treated with MC/pmIL-12. Source: From Ref.

Google Scholar